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BRCA1 and BRCA2 mutations have been identified in 107 families in Scotland and Northern Ireland. Ninety-seven of these families
had been referred to regional cancer genetics centres and a further 10 were identified from a sequential series of male breast cancers
treated in Edinburgh. Fifty-nine of the families had a mutation in BRCA1 and 46 in BRCA2. Two families had both. Family trees were
extended and cancer diagnoses verified by means of the unusually complete and accessible Scottish and Northern Irish records. Ten
specific recurring mutations (five in each gene) accounted for almost half of the total detected, and almost one-quarter were
accounted for by just two (BRCA1 2800 delAA and BRCA2 6503 delTT). The prevalence of breast cancer is similar for BRCA1 and
BRCA2 mutation families (average 3.7 and 3.6 per family), but the former have a much greater risk of ovarian cancer (average 1.5 and
0.6 per family, respectively). For breast cancer, age of onset tended to be younger in BRCA1 mutation carriers but, for ovarian cancer,
there was no difference between BRCA1 and BRCA2 families in mean age at diagnosis. Mutations within the 50 two-thirds of BRCA1
carry a significantly higher relative risk of ovarian cancer and the same is true for mutations within the central portion of BRCA2 (the
‘OCCR’). In the former case, this appears to be because of differences in absolute risk for both ovarian and breast cancer, while, in the
latter, only ovarian cancer risk varies significantly. The findings confirm that founder mutations are present within the Scottish/
Northern Irish population and have implications for the organisation of molecular screening services.
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Worldwide variation in the distribution of BRCA1 and BRCA2
mutations is well recognised (Szabo and King, 1997). In several
populations or ethnic groups, distinctive founder mutations form a
sufficient proportion of the total to justify the adoption of specific
molecular screening strategies (Levy-Lahad et al, 1997; Peelen et al,
1997; Thorlacius et al, 1997; Moller et al, 2001). In the UK, there
has been only limited evidence to date of founder mutations
(Gayther et al, 1995, 1997; Eccles et al, 1998; Lancaster et al, 1998;
Peto et al, 1999), the most clear-cut example being BRCA1 2800
delAA, probably originating from the West of Scotland or Ireland
(Liede et al, 2000). Since the present day populations of Scotland
and Northern Ireland remain relatively homogeneous, and distinct
from those of other parts of the UK (Bodmer et al, 1987; Liede et al,
2000), we have collated information on all BRCA1 and BRCA2
mutations recorded among families attending breast cancer
genetics clinics in Aberdeen, Belfast, Dundee, Edinburgh or
Glasgow. Additional data are included from a sequential series of
male breast cancers presenting in South-East Scotland (Young et al,
2000). Findings are compared with those reported from England,
Wales and elsewhere.
In both Scotland and Northern Ireland, families have tended to
be large, at least until the current generation. They are also,
typically, close-knit, maintaining contact even with members who
have emigrated to distant parts of the world. Records of births,
marriages and deaths are unusually complete and accessible
(Collyer and DeMey, 1987) and the Scottish Cancer Registry, in
particular, is recognised as among the best in the world (Kemp
et al, 1985). For all these reasons, data on Scottish and Northern
Irish families with genetic disorders can be extensive and accurate.
The present data set, based on over 100 mutation-bearing families,
is therefore of value for addressing questions about the clinical
implications of BRCA1 and BRCA2 mutations.
PATIENTS, FAMILIES AND METHODS
The study was approved by the Medical Research Ethics
Committee for each of the regions in which clinical genetics
services are based. The five centres mentioned above provide
comprehensive National Health Service (NHS) clinical services for
familial cancers, covering the entire population. They have
collaborated closely in the design and development of these
services for some 10 years and follow common policies on
eligibility for regular surveillance by clinical/mammographic and
ovarian screening (Haites et al, 2000). Molecular testing for BRCA1
or BRCA2 mutations was available only on a research basis from
1994 until 2001, when NHS funding was provided to establish a
laboratory service accessible to all high-risk families. The majority
of mutations included in this report were identified in one of the
Scottish or Northern Irish research centres but some were found in
family members tested at the Institute of Cancer Research, London
(Dr Simon Gayther, Prof Michael Stratton), the University of Lund
(Dr Ake Borg) or in centres in the USA, Australia, Iceland and the
Netherlands. Mutation-detection methods therefore varied but, in
general, they have been based on PCR amplification of gene
fragments, covering most of the coding regions and splice sites,
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sfollowed by SSCP or heteroduplex analysis on gels (Gayther et al,
1995, 1996) or, more recently, by DHPLC (Wagner et al, 1999).
Protein truncation assay (Hogervorst et al, 1995) has been applied
on a limited scale and 150 samples from ‘high-risk’ families were
screened specifically for the 6kb duplication in BRCA1 exon 13,
with one positive result (Mazoyer et al, 2000). Only some 20 ‘high-
risk’ Scottish families have been included in a preliminary screen
for large deletions in BRCA1. None has yet been found. Some
centres have concentrated on screening those regions of both
genes where mutations have already been identified in our
population. This is likely to increase the apparent frequency of
recurrent mutations but it is difficult to quantify the effect. The
bulk of the screening was undertaken without this bias and, where
priority was given to examination of particular PCR fragments,
these, in total, represent a significant proportion of the entire
coding regions of BRCA1 and BRCA2, so that nonrecurring
mutations could be (indeed were) detected in the process. All
mutations have been confirmed by direct sequencing and
reconfirmed on a second blood sample from the index case before
offering counselling and access to genetic testing for at-risk adult
members of the family.
Family trees have been constructed, initially from information
provided by families themselves. In most instances, they have filled
out detailed family history forms, issued on referral to a genetics
clinic. This normally entails a collaborative effort on the part of
several family members, across the generations. Verification and
extension of pedigrees can be undertaken by consulting public
registration records (Collyer and DeMey, 1987) which, in
comprehensive form, date from 1855. This facility, supported by
a professional medical genealogist, is used selectively but when a
germline mutation is detected, record tracing becomes a priority,
since the process can establish links between two or more families
already known to the clinics.
All practicable efforts are made to verify reported cancer
diagnoses in the family, particularly if it seems probable that the
pattern of disease is attributable to a high penetrance mutation.
Confirmation can be obtained, in the case of deceased subjects, by
consulting the Scottish or Northern Irish cancer registries (good
data are available from mid-1960s onwards). For living patients,
permission is sought to check relevant details from hospital
records. In some instances, particularly for cancers that occurred
over 40 years ago, supporting evidence can be obtained only from
death certificates and, on occasions, there is no means of
verification. A judgement then has to be made, on the basis of
the family’s own knowledge, whether or not to record a given
relative as being affected by breast, ovarian or other cancers. When
a mutation has been identified in one member of a given family,
blood samples or tissue blocks are sought from affected relatives,
to establish their mutation status. The process of tracing the
distribution of the mutant allele within each family is still ongoing.
In a number of cases, affected relatives have been shown not to
carry the ‘family mutation’. These individuals are usually then
reclassified as having sporadic cancer (with correspondingly
reduced risk estimates for their descendants) but in two families
a second mutation has been found and, in a few more, the pattern
of cancers on both sides of the pedigree would be consistent with
the presence of a second, still unidentified, mutation.
In the main, families selected for molecular testing met the
published criteria (Haites et al, 2000) for, at least, ‘moderate risk’
(i.e. two close relatives with early onset breast or ovarian cancer)
and most met the more stringent criteria defining ‘high risk’. Two
exceptions were a single positive result from a consecutive series of
women diagnosed with breast cancer under age 50 and one patient
who had only a single relative with breast cancer, but an unusual
familial cluster of early onset prostate, stomach and laryngeal
cancers. She herself might have been discharged but was found to
have breast cancer on her first clinic visit and a BRCA2 mutation
was subsequently demonstrated. Twelve BRCA2 mutations have
been identified among DNA samples from a consecutive series of
64 male breast cancers treated in Edinburgh since 1975. These
samples were analysed, in the first instance, without reference to
family history (Young et al, 2000). Most of the patients are
deceased and construction of complete family trees is still
proceeding, with the cooperation of their living relatives. However,
two of them belong to families already registered with the regional
cancer genetics clinic (because a cluster of cases among relatives
had been recognised). In addition to the 12 from the consecutive
series, a further 10 instances of male breast cancer have been
recorded among the BRCA2 mutation-positive families in the
present report. Two of these families included more than one
affected male (three and two cases each).
RESULTS
One hundred and nine mutations (61 in BRCA1, 48 in BRCA2)
have been identified in 107 families. The vast majority cause
truncation of the protein product (89 frame-shifts, six nonsense
substitutions, eight splice site disruptions). One is a 6kb
duplication of BRCA1 exon 13 and there are two instances of an
intronic deletion believed to affect splicing (BRCA2 9877-67 del4).
Only three missense substitutions are included. Two of these are
recognised as pathogenic by the Breast Cancer Information Core
(BIC) database and the third, BRCA1 5242C4A, although still
listed as an unclassified variant, has been recorded 13 times in
multicase breast cancer families.
Several mutations have been identified in more than one family
each. Two are particularly frequent, BRCA1 2800 delAA and
BRCA2 6503 delTT. The former has already been identified as a
Scottish/Irish founder mutation (Liede et al, 2000), while the latter
is also a recognised founder mutation, distributed throughout
Europe and the USA (Mazoyer et al, 1996; Szabo and King, 1997;
BIC database). In contrast to BRCA1 2800 delAA, the BRCA2 6503
delTT mutation is relatively frequent among families attending the
Aberdeen and Dundee clinics (representing the North and East of
Scotland), which may be in keeping with Scandinavian origin
(Table 1).
Eight further mutations, each detected at least three times,
account for 27 families. Two of the three recognised Ashkenazi
Jewish mutations (Levy-Lahad et al, 1997) –BRCA1 185 delAG and
BRCA1 5382 insC –are among these eight; the third, BRCA2 6174
delT, was found on two occasions. The overall distribution of
mutations is set out in Figure 1.
In assessing the numbers of breast and ovarian cancers recorded
in mutation-positive families, two families have been excluded
(both with BRCA2 mutations). One was identified through the
consecutive series of male breast cancers and no information has
yet been obtained about relatives. The other has been counted as a
BRCA1 mutation family, although a single BRCA2 mutation-
Table 1 Geographical distribution of BRCA1 and BRCA2 founder
mutations
BRCA1 2800 delAA BRCA2 6503 delTT
Aberdeen 0 4
Dundee 1 4
Edinburgh 4 1
Glasgow 7 5
Belfast 2 0
Numbers of families with founder mutations BRCA1 2800 delAA or BRCA2 6503
delTT attending each of the five clinics in Scotland/Northern Ireland. Some families,
with branches in different parts of the country, are recorded as attending more than
one clinic. Clinics are listed in geographical sequence from North-East (Aberdeen) to
South-West (Belfast).
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scarrier has been identified in one branch of the pedigree. That
branch has not yet been investigated in detail. For the other family
with two mutations (BRCA1 and BRCA2), it has been possible to
identify the separate routes of inheritance and hence to calculate
the numbers of breast and ovarian cancers attributable to each
mutation. For all families, where an affected individual has been
found not to carry the BRCA1 or BRCA2 mutation, that tumour
has not been included in the calculations and, of course, only
tumours occurring in blood relatives of mutation-positive family
members are counted. Overall, comparable effort has been
expended on gathering and verification of data on BRCA1 and
BRCA2 mutation families. As shown in Table 2, the average
number of breast cancers recorded per family is virtually the same
for both mutations, but there are two and a half times as many
ovarian cancers in BRCA1 families. The ratio of breast to ovarian
cancers is 2.39:1 for BRCA1 families and 6.18:1 for BRCA2
families, a difference which is significant at the 0.01% level by w
2
analysis. This is consistent with data from the Breast Cancer
Linkage Consortium (Ford et al, 1998) and other sources (Risch
et al, 2001; Welcsh and King, 2001).
The mean age at diagnosis of breast cancer in BRCA1 mutation
carriers was 42.6 years (95% CI 40.5–44.8). For BRCA2 mutation
carriers (females only), it was 46.5 years (95% CI 43.6–49.4). Half
of those with BRCA1 mutations were diagnosed at or below age 40,
compared with just over one-quarter of those with BRCA2
mutations. For affected males (all with BRCA2 mutations), mean
age at diagnosis of breast cancer was 59.4 years (95% CI 51.9–
67.0). In keeping with the younger age at onset, 56% of BRCA1
families included at least one instance of bilateral disease,
compared to 28% of BRCA2 families. (In the latter set, there was
one male with bilateral breast cancers, onsets separated by 22
years.) Furthermore, in 36% of BRCA1 families, but fewer than
10% of BRCA2 families, there were two or more examples of
bilaterality. Individual women with both breast and ovarian cancer
were recorded in 36% of BRCA1 families, with up to three
instances per family, whereas they occurred in only 10% of BRCA2
families and no family included more than one case. Ages of onset
for ovarian cancer did not differ between families with BRCA1 or
BRCA2 mutations (49.7 years, 95% CI 46.9–52.4 and 49.8 years,
95% CI 43.0–56.6 years, respectively). Over 90% of ovarian
cancers, in both sets of families, were diagnosed at age 40 or older
and half of the remainder were diagnosed at age 39.
A rather more contentious issue is the effect of mutation
position, within either gene, on the relative risk of breast or
ovarian cancer (Gayther et al, 1995; Iau et al, 2001; Thompson et al,
2001). For BRCA1, there is evidence that mutations towards the 30
end are less likely to be associated with ovarian cancer (Gayther
et al, 1995). We have subdivided our BRCA1 families as shown in
Tables 3A, B, and confirm that the ratio of breast to ovarian
cancers is strongly influenced by mutation site. Interestingly, our
data suggest that this may result from both an increase in breast
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Figure 1 Diagrammatic representation of BRCA1 exons (plus intronic regions with pathogenic mutations, shown shaded). Vertical lines above the
diagram represent all mutations detected, with heights proportional to numbers of cases. Actual numbers are given for most frequent mutations. Circles
below the diagram represent families with at least three breast or ovarian cancers attributed to each mutation. The darker segment of each circle represents
the proportion of breast cancers and the paler segment the proportion of ovarian cancers.
Table 2 Breast and ovarian cancers recorded in BRCA1 and BRCA2
mutation-bearing families
BRCA1 mutation +ve BRCA2 mutation +ve
No. of families 61 46
No. of breast cancers 225 167
No. of ovarian cancers 94
a 27
b
Av. breast cancers/family 3.7 3.6
Av. ovarian cancers/fam 1.5 0.6
Ratio CaBr/CaOv 2.39:1 6.19:1
aIncludes one primary peritoneal carcinoma.
bIncludes one primary carcinoma of
fallopian tube.
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scancer risk and a reduction in ovarian cancer risk when the
mutation occurs 30 of exon 11.
For BRCA2, it has been proposed that mutations within the
central region of the gene, termed the ovarian cancer cluster region
(‘OCCR’), are particularly associated with ovarian cancers
(Figure 2). Our data show that the ratio of breast to ovarian
cancers is 4.81:1 for mutations within the OCCR and 11.0:1 for
mutations 30 and 50 of that region. When the families identified
only through the male breast cancer study are excluded, the trend
for ovarian cancer remains in the same direction (4.04 breast
cancers and 0.84 ovarian cancer per family within OCCR, 4.33
breast cancers and 0.50 ovarian cancers per family outside it; ratios
4.81:1 and 8.67:1, respectively) but the differences are no longer
statistically significant.
DISCUSSION
The proportion of BRCA2 mutation-bearing families in the present
series (44%) is higher than that has been estimated indirectly from
earlier (mainly much smaller) studies from the UK (Szabo and
King, 1997; Lancaster et al, 1998). However, it is consistent with
the prediction of roughly equal prevalence of BRCA1 and BRCA2
mutations, based on a survey of very early onset breast cancers
(Peto et al, 1999). The authors of that survey noted that several UK
studies have concentrated on multicase families in which ovarian
cancer was prominent, thus overestimating the relative frequency
of BRCA1 mutations. The International Breast Cancer Linkage
Consortium data show that, among families with multiple cases of
breast cancer but no known ovarian cancers, BRCA1 and BRCA2
mutations are almost equally represented (Ford et al, 1998). In the
present series, there was no particular emphasis on ovarian cancer
in selecting families for mutation testing but, of course, the
clustering of ovarian with breast cancer in a family adds
considerably to the prior probability of a mutation being present,
as also does the occurrence of very early onset breast cancer.
Account is taken of both these facts in the Scottish NHS guidelines
123 456 7 8 9 10 11a 11b 11c 11d 11e 11f 12 13
3 3 3 3
12
14 15 16 17 18 1920 21 22 23 2425 26 27
OCCR
9
5
2
2
 
C
>
G
9
2
9
7
 
d
e
l
8
9
1
3
2
 
d
e
l
C
8
5
6
0
-
1
 
G
>
C
8
5
2
5
 
d
e
l
T
7
8
3
0
 
d
e
l
1
6
7
1
6
5
+
2
d
e
l
2
6
1
7
4
 
d
e
l
T
T
5
9
1
0
 
C
>
G
5
8
0
4
 
d
e
l
4
5
5
7
4
 
d
e
l
A
A
5
4
4
5
 
d
e
l
7
4
3
9
1
 
d
e
l
C
T
 
i
n
s
 
A
4
2
3
6
 
i
n
s
4
4
0
7
5
 
d
e
l
G
T
3
0
1
4
 
d
e
l
T
2
1
5
7
 
d
e
l
G
2
0
2
2
 
d
e
l
5
1
4
1
8
 
i
n
s
4
9
9
9
 
d
e
l
5
9
8
3
 
d
e
l
4
9
8
7
7
-
6
7
 
d
e
l
4
6
5
0
3
 
d
e
l
T
T
Figure 2 Diagram of BRCA2 exons, with the position of the ‘OCCR’ indicated. Annotation and symbols are as for Figure 1.
Table 3 Distribution of breast and ovarian cancers in families, according
to site of (A) BRCA1 and (B) BRCA2 mutation
(A) BRCA1 mutations
50 of exon 12
BRCA1 mutations
exons 12–24
Number of families 49 12
No. of breast cancers 161 64
No. of ovarian cancers 82 12
Average CaBr/family 3.3
a 5.3
a
Average CaOv/family 1.7 1.0
Ratio CaBr/CaOv 1.96:1
b 5.33:1
b
(B) BRCA2 mutations
within ‘OCCR’
BRCA2 mutations
outside ‘OCCR’
Number of families 25 21
No. of breast cancers 101 66
No. of ovarian cancers 21 6
Average CaBr/family 4.0 3.1
Average CaOv/family 0.84
c 0.29
c
Ratio CaBr/CaOv 4.81:1
d 11:1
d
aDifference in risks of breast cancer P¼0.001 (by w
2).
bDifference in relative risks of
breast vs ovarian cancer, P¼0.0002 (by w
2).
cDifference in risks of ovarian cancer
Po0.02 (by w
2).
dDifference in relative risks of breast vs ovarian cancer Po0.005
(by w
2).
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sfor management of familial cancers (Haites et al, 2000), hence
favouring ascertainment of BRCA1 mutation-bearing families. In
most centres, facilities for BRCA1 mutation testing became
available at least a year before those for BRCA2 so that, in
consecutive series, there is some bias in favour of detecting BRCA1
mutations. This applies to the present data set, although the effect
is probably not great and should diminish with time. On the other
hand, our inclusion of 10 BRCA2 mutations detected only through
a survey of male breast cancers obviously introduces a bias in the
opposite direction. Nevertheless, it appears that in Scotland and
Northern Ireland, the relative prevalence of BRCA2 mutations may
be higher than in some other regions of Europe such as Norway
(Moller et al, 2001), Sweden (Hakansson et al, 1997), Belgium
(Claes et al, 1999) or France (Serova-Sinilnikova et al, 1997;
Stoppa-Lyonnet et al, 1997).
Our findings do not permit any calculation of the absolute
prevalence of BRCA1 or BRCA2 mutations in the Scottish and
Northern Irish populations but they add to our knowledge of the
distribution of specific mutations. Allowing for some bias in
ascertainment, as discussed above, almost one-quarter of the
families are accounted for by just two (BRCA1 2800 delAA and
BRCA2 6503 delTT) and almost half by the 10 mutations that were
found in at least three families each. Two of these are the well-
recognised ‘Ashkenazi Jewish’ BRCA1 mutations (185 delAG and
5382 insC), although at least one of the affected families is unaware
of any Ashkenazi Jewish ancestry. The other recurring mutations
are BRCA1 3477 delGT and 4184 del4, BRCA2 1418 ins4, 5445 del7,
7165þ2 delT, 7830 del16. Most of these have been recorded many
times in the BIC database and/or the Human Gene Mutation
Database. Our earlier speculation (Liede et al, 2000) that BRCA1
2800 delAA may have originated in West-Central Scotland or in
Ireland seems to be supported by the finding of three further cases,
one from Glasgow and two from Belfast. BRCA2 6503 delTT has
been found elsewhere in the UK as well as in Dutch, Swedish,
Danish and Belgian families (BIC database). It was the most
frequently recurring BRCA2 mutation (four examples) among 25
recorded by Gayther et al (1997) from ‘the United Kingdom and
Eire’ but no further breakdown by geographical region was
provided. BRCA1 4184 del4 was identified as a recurring mutation
in that survey and also in separate reports of families from Wales
and the South of England (Lancaster et al, 1998; Eccles et al, 1998).
In the last-mentioned study, BRCA1 3875 was found five times in a
total series of 17 mutations. It is entirely possible that further
examples may be found of founder mutations associated with
specific populations concentrated in particular regions of the UK
but larger studies will be required. Scotland and Northern Ireland
offer special advantages for this kind of analysis because of the
relative population stability, the existence of an NHS-funded
cancer genetics network and the excellence of genealogical and
health-related records.
The proportion of all breast or breast/ovarian cancer families in
our population attributable to recurring BRCA1 or BRCA2
mutations appears to be lower than in some other countries such
as Iceland (Thorlacius et al, 1997), Israel (Levy-Lahad et al, 1997)
or Norway (Moller et al, 2001), comparable to that in the
Netherlands (Peelen et al, 1997; Claes et al, 1999), but much
higher than in others, such as Italy (Szabo and King, 1997;
Cippolini et al, 1999), and sufficient to have practical implications
for the formal organisation of molecular screening. A first-stage
analysis, covering the 10 most common BRCA1 and BRCA2
mutations, using multiplex PCR/DHPLC is rapid and relatively
inexpensive. It can be offered to substantial numbers of families,
then, if a negative result is obtained, more stringent risk criteria
can be applied for complete analysis of the genes. This policy is
already identifying further mutation-positive families (not in-
cluded in the present report) among those who would not
currently be eligible for full-scale molecular screening in our
diagnostic laboratories (Haites et al, 2000). The occurrence of
identical mutations in many families also provides opportunities
for investigation of genetic and environmental factors that may
modify penetrance or expression of the underlying mutation. This
principle has been applied, for example, to identify an interaction
between BRCA2 mutations and a polymorphism of RAD51 (Levy-
Lahad et al, 2001; Wang et al, 2001). Among the families recorded
here is one with seven cases of ovarian cancer over four
generations, but no breast cancers. No other family with the same
mutation, from the present series or from the BIC database, shows
a comparable distribution of tumours and further research is
warranted to establish whether this is merely a chance finding or a
clue to an additional causal factor.
The influence of mutation site on relative risk of breast or
ovarian cancer has been a controversial issue. For BRCA1, two
studies published in 1995 indicated that the relative risk of ovarian
cancer was substantially higher for mutations occurring in the 50
two-thirds of the gene (Gayther et al, 1995; Shattuck-Eidens et al,
1995) but this was not confirmed in three other reports (Serova
et al, 1996; Couch et al, 1997; Frank et al, 1998) and is not apparent
in a fourth (Eccles et al, 1998), where the data are presented but
not discussed in detail. Taking the 30 end of exon 11 as the
potential ‘change point’, we found a highly significant difference in
the relative proportions of breast and ovarian cancers ‘upstream’
and ‘downstream’ of this position. Furthermore, the difference
seems to arise both from an increased risk of breast cancer and a
reduced risk of ovarian cancer for mutations in the 30 third
of the gene, although the difference in numbers of breast cancers
per family does not achieve statistical significance on its own
(Po0.1).
For BRCA2, an ‘Ovarian Cancer Cluster Region’ in the middle
third of the gene was proposed by Gayther et al (1997). An
international collaborative study (Neuhausen et al, 1998) provided
some supporting evidence which, however, failed to reach
statistical significance. In a more recent analysis of 164 BRCA2
mutation-bearing families (Thompson et al, 2001), 23.8% of
tumours were ovarian (and 76.2% breast) among families with
OCCR mutations: for families with mutations 50 and 30 of the
OCCR, 8.8 and 9.6%, respectively, were ovarian cancers. Our own
findings are similar but, whereas Thompson and colleagues found
that a reduced absolute risk of breast cancer for OCCR mutations
contributes substantially to the effect, in our series, the number of
breast cancers per family is actually higher for OCCR vs non-OCCR
mutations, and the entire increase in relative risk of ovarian cancer
is attributable to a 2.9-fold higher rate of ovarian cancers in the
former group. It will be important to determine which of these
interpretations is correct in order to generate testable biological
hypotheses to explain the findings.
The validity of our analysis depends on completeness of
ascertainment of families and accuracy of breast and ovarian
cancer diagnoses. There are obviously limitations on both counts
but the large average family size, the accessibility of confirmatory
records and the uniformity of our approach to extension and
verification of family data allow some confidence in our data.
Excluding nine families ascertained only through a series of male
breast cancers (one such family was already excluded for lack of
information) greatly reduces the statistical power of our analysis. It
happens that all of these nine families carried mutations outside
the OCCR and that none included any case of ovarian cancer.
However, there is no indication that these are particular
characteristics of BRCA2 mutations associated with male breast
cancer. Six of the families with mutations inside the OCCR
included affected males (two with more than one male case each)
and two of these also included ovarian cancers.
Whether the associations between mutation position and
phenotype are sufficiently strong to influence genetic counselling
and management of affected families remains a moot point.
Individual families, where the distribution of cancers seems to
depart from the general rules, are not rare and, for the present, it
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history of the family in question as of the statistical findings from
large-scale surveys.
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